Erasca

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Our mission is to redefine cancer care by making therapeutic solutions safe, accessible, and affordable for everyone. We are dedicated to finding cures for cancer by developing innovative treatments that harness the power of precision medicine and a patient-centric approach.

We envision a world where everyone has access to the best cancer care and where no one has to suffer from the challenges of this disease. We envisage a future where precision medicine is the norm and everyone is empowered with tailored information and support.

Erasca has been recognized internationally for its innovative approach to drug development. We have been awarded numerous awards and honors, including the Food and Drug Administration Breakthrough Therapy Designation and the National Institutes of Health Most Innovative Award.